Elevation Point Wealth Partners LLC Acquires 7,263 Shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO)

Elevation Point Wealth Partners LLC grew its stake in Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) by 128.0% in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 12,936 shares of the biopharmaceutical company's stock after acquiring an additional 7,263 shares during the period. Elevation Point Wealth Partners LLC's holdings in Halozyme Therapeutics were worth $825,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors also recently modified their holdings of HALO. Smartleaf Asset Management LLC grew its position in shares of Halozyme Therapeutics by 29.2% during the 4th quarter. Smartleaf Asset Management LLC now owns 871 shares of the biopharmaceutical company's stock worth $42,000 after buying an additional 197 shares during the period. Louisiana State Employees Retirement System lifted its holdings in Halozyme Therapeutics by 0.6% in the fourth quarter. Louisiana State Employees Retirement System now owns 35,300 shares of the biopharmaceutical company's stock valued at $1,688,000 after buying an additional 200 shares during the period. Parallel Advisors LLC boosted its stake in Halozyme Therapeutics by 12.5% in the first quarter. Parallel Advisors LLC now owns 1,875 shares of the biopharmaceutical company's stock valued at $120,000 after acquiring an additional 208 shares during the last quarter. Baird Financial Group Inc. grew its holdings in Halozyme Therapeutics by 2.0% during the 4th quarter. Baird Financial Group Inc. now owns 11,119 shares of the biopharmaceutical company's stock worth $532,000 after acquiring an additional 221 shares during the period. Finally, Portside Wealth Group LLC raised its position in shares of Halozyme Therapeutics by 2.4% during the 1st quarter. Portside Wealth Group LLC now owns 9,317 shares of the biopharmaceutical company's stock valued at $595,000 after acquiring an additional 222 shares during the last quarter. 97.79% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several research analysts have recently issued reports on HALO shares. Benchmark lowered Halozyme Therapeutics from a "strong-buy" rating to a "hold" rating in a research report on Wednesday, May 7th. Wells Fargo & Company boosted their target price on Halozyme Therapeutics from $60.00 to $65.00 and gave the stock an "equal weight" rating in a research report on Wednesday, May 7th. JPMorgan Chase & Co. upped their price target on Halozyme Therapeutics from $55.00 to $58.00 and gave the company a "neutral" rating in a research note on Monday, April 21st. Leerink Partnrs lowered shares of Halozyme Therapeutics from a "hold" rating to a "strong sell" rating in a research note on Tuesday, May 13th. Finally, Morgan Stanley cut shares of Halozyme Therapeutics from an "overweight" rating to an "equal weight" rating and decreased their price objective for the company from $73.00 to $62.00 in a report on Wednesday, May 14th. Two investment analysts have rated the stock with a sell rating, six have given a hold rating and four have given a buy rating to the company's stock. According to MarketBeat.com, Halozyme Therapeutics currently has an average rating of "Hold" and an average price target of $61.90.

Insider Transactions at Halozyme Therapeutics

In related news, Director Jeffrey William Henderson sold 4,497 shares of the business's stock in a transaction on Monday, April 28th. The shares were sold at an average price of $60.37, for a total transaction of $271,483.89. Following the transaction, the director now directly owns 28,611 shares in the company, valued at approximately $1,727,246.07. The trade was a 13.58% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Company insiders own 2.90% of the company's stock.

Halozyme Therapeutics Stock Up 0.4%

NASDAQ HALO traded up $0.20 on Wednesday, reaching $53.31. The company had a trading volume of 791,346 shares, compared to its average volume of 1,632,549. The company's fifty day moving average is $57.12 and its 200-day moving average is $56.20. The firm has a market capitalization of $6.57 billion, a price-to-earnings ratio of 14.17, a price-to-earnings-growth ratio of 0.36 and a beta of 1.19. The company has a debt-to-equity ratio of 3.13, a quick ratio of 7.30 and a current ratio of 8.39. Halozyme Therapeutics, Inc. has a 1-year low of $42.01 and a 1-year high of $70.51.

Halozyme Therapeutics (NASDAQ:HALO - Get Free Report) last posted its quarterly earnings data on Tuesday, May 6th. The biopharmaceutical company reported $1.11 earnings per share for the quarter, topping the consensus estimate of $0.98 by $0.13. Halozyme Therapeutics had a return on equity of 136.91% and a net margin of 44.76%. The company had revenue of $264.86 million during the quarter, compared to analysts' expectations of $231.21 million. During the same period in the prior year, the firm earned $0.79 earnings per share. Halozyme Therapeutics's revenue for the quarter was up 35.2% compared to the same quarter last year. On average, research analysts forecast that Halozyme Therapeutics, Inc. will post 4.73 earnings per share for the current fiscal year.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.